SAREPTA THERAPEUTICS, INC. Interest on Convertible Debt, Net of Tax
SAREPTA THERAPEUTICS, INC. (SRPT) reported Interest on Convertible Debt, Net of Tax of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Earnings Per Share
us-gaap:InterestOnConvertibleDebtNetOfTax · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. interest on convertible debt, net of tax for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. interest on convertible debt, net of tax for the quarter ending 2026-03-31 was $19.90M.
- SAREPTA THERAPEUTICS, INC. interest on convertible debt, net of tax for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. interest on convertible debt, net of tax for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. interest on convertible debt, net of tax for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. interest on convertible debt, net of tax for fiscal 2024 was $17.00M.
- SAREPTA THERAPEUTICS, INC. interest on convertible debt, net of tax for fiscal 2023 was $0.00.
- SAREPTA THERAPEUTICS, INC. interest on convertible debt, net of tax for fiscal 2022 was $0.00.
| Period end | Interest on Convertible Debt, Net of Tax 3 month | Interest on Convertible Debt, Net of Tax 6 month | Interest on Convertible Debt, Net of Tax 9 month | Interest on Convertible Debt, Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $39.68M 10-Q · filed 2026-08-05 | $19.90M derived: sum of 3 quarters · filed 2026-08-05 | $19.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $19.90M 10-Q · filed 2026-05-06 | $19.90M derived: sum of 2 quarters · filed 2026-05-06 | $19.90M derived: sum of 3 quarters · filed 2026-05-06 | $24.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $4.30M derived: sum of 3 quarters · filed 2026-08-05 | $0.00 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $4.30M derived: sum of 2 quarters · filed 2026-08-05 | $0.00 10-Q · filed 2025-11-06 | $20.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.30M 10-Q · filed 2026-08-05 | $4.30M derived: sum of 2 quarters · filed 2026-08-05 | $20.12M derived: sum of 3 quarters · filed 2026-08-05 | $20.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $15.82M derived: sum of 2 quarters · filed 2026-05-06 | $16.23M derived: sum of 3 quarters · filed 2026-05-06 | $16.57M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $15.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $16.23M derived: sum of 2 quarters · filed 2026-03-02 | $16.57M derived: sum of 3 quarters · filed 2026-03-02 | $17.00M 10-K · filed 2026-03-02 |
| 2024-09-30 | $413.00K 10-Q · filed 2025-11-06 | $753.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.18M 10-Q · filed 2025-11-06 | $1.18M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $340.00K 10-Q · filed 2025-08-06 | $769.00K 10-Q · filed 2025-08-06 | $769.00K derived: sum of 3 quarters · filed 2026-03-02 | $769.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $429.00K 10-Q · filed 2025-05-06 | $429.00K derived: sum of 2 quarters · filed 2026-03-02 | $429.00K derived: sum of 3 quarters · filed 2026-03-02 | $429.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-01 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |